Ligand-grafted long circulation liposome and nuclear medicine
Ma, C.; Kuang, A.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24(5): 1200-1204
2007
ISSN/ISBN: 1001-5515 PMID: 18027727 Document Number: 613516
Ligand-grafted long circulation liposome is an advanced and effective carrier in which drugs are modified to be stabilized in the body and delivered properly in time and amount at targeted organs with suppressing side effects.
Document emailed within 1 workday
Related Documents
Wang, W.; Yang, T.; Liu, L.; Pei, F. 2014: Proteomics study on effect of basic fibroblast growth factor long circulation liposome on spinal cord traction injury in rats Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 28(11): 1397-1405Kappert, A.; Rösler, H. 1973: Nuclear medicine analysis of the peripheral circulation by means of 99m-technetium Schweizerische Medizinische Wochenschrift 103(31): 1087-1093 Contd
Cao, M.; Deng, H-Xin.; Zhao, J.; Fan, L-yu.; Jiang, Y.; Wen, Y-Jun.; Li, J.; Lei, S.; Mao, Y-qiu.; Ding, Z-Yu.; Wei, Y-quan. 2007: Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene Biotechnology and Applied Biochemistry 48(Pt 2): 109-116
Poppitz, R. 1982: Patient exposure and radiation risk in Bulgarian diagnostic nuclear medicine. I. Survey of diagnostic nuclear medicine procedures in Bulgaria in 1980 Nuklearmedizin. Nuclear Medicine 21(3): 85-91
Van Bezooijen, R.L.; Papapoulos, S.E.; Löwik, C.W. 2001: Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? Bone 28(4): 378-386
Cuarón Santiesteban, A. 1987: 10 years of nuclear cardiology. (I). Clinical development and technological progress in nuclear medicine at the Ignacio Chávez National Cardiological Institute Archivos del Instituto de Cardiologia de Mexico 57(5): 403-413
Mackiewicz, Z.; Salo, J.; Konttinen, Y.T.; Kaigle Holm, A.; Indahl, A.; Pajarinen, J.; Holm, S. 2009: Receptor activator of nuclear factor kappa B ligand in an experimental intervertebral disc degeneration Clinical and Experimental Rheumatology 27(2): 299-306
Alatab, S.; Maghbooli, Z.; Hossein-Nezhad, A.; Khosrofar, M.; Mokhtari, F. 2011: Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes Minerva Medica 102(6): 461-468
Im, C.H.; Kang, E.H.; Ki, J.Y.; Shin, D.W.; Choi, H.J.; Chang, E.J.; Lee, E.Y.; Lee, Y.J.; Lee, E.B.; Kim, H.H.; Song, Y.W. 2009: Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis Clinical and Experimental Rheumatology 27(4): 620-625
Coetzee, M.; Kruger, M.C. 2004: Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? Southern Medical Journal 97(5): 506-511
Kamarei, A.; Wong, A.; McCalden, T. 1989: Methodology for efficacy study of liposome bronchodilators in long duration experiments Proceedings of the Western Pharmacology Society 32: 33-35
Brandau, W. 1994: Guidelines for radiation protection in medicine--radiopharmaceutical quality control. German Society of Nuclear Medicine Nuklearmedizin. Nuclear Medicine 33(2): 118-124
Wang, S.Z. 1981: [Lecture: an important branch of modern medicine---nuclear medicine Zhonghua Nei Ke Za Zhi 20(6): 367-370
Gregoriadis, G.; Neerunjun, D.; Meade, T.W.; Goolamali, S.K.; Weereratne, H.; Bull, G. 1980: Experiences after long-term treatment of a type i Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase Birth Defects Original Article Series 16(1): 383-392
Frassoni, F.; Martinelli, G.; Saglio, G.; Sessarego, M.; Podestà, M.; Piaggio, G.; Farabegoli, P.; Zaccaria, A.; Testoni, N.; Remiddi, C. 1995: bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase Bone Marrow Transplantation 16(4): 595-601
Kwan Tat, S.; Pelletier, J.-P.; Lajeunesse, D.; Fahmi, H.; Lavigne, M.; Martel-Pelletier, J. 2008: The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells Clinical and Experimental Rheumatology 26(2): 295-304
Pohlen, U.; Berger, G.; Jung, M.; Rezska, R.; Regenstein, J.; Buhr, H.J. 1998: Tumor regression in long-term follow-up by administration of liposome encapsulated 5-FU. An animal experiment in WAF rats with CC-531 liver tumor Langenbecks Archiv für Chirurgie. Suppl. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 115(Suppl I): 625-629
Wolfer, G.K.; Rippon, W.B. 1987: Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions Clinical Chemistry 33(1): 115-117
Gryzunov, I.A.; Komarova, M.N. 2004: A study of ligand binding to protein using resonance energy transfer from the isoindole fluorescent label to ligand Biofizika 49(6): 979-986
Matsui, K.; Fine, A.; Zhu, B.; Marshak-Rothstein, A.; Ju, S.T. 1998: Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma Journal of Immunology 161(7): 3469-3473